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The Efficacy of Tenofivir to Prevent Perinatal Transmission in 
Chronic Hepatitis B Mothers. A Clinical Perspective
TO THE EDITOR:
With great satisfaction, we read the April 2018 
American Association for the Study of Liver 
Diseases (AASLD) guidelines for the management 
of chronic hepatitis B propose that pregnant women 
with hepatitis B virus (HBV) receive tenofovir in the 
third trimester, for viral loads greater than 200,000 
IU/mL.(1)
Surprisingly, the first double-blinded, randomized, 
controlled trial on this subject, released in the March 
8 issue of the New England Journal of Medicine, found 
no significant difference between fetal viral loads of a 
group of 147 women who received tenofovir begin-
ning at 28 weeks and those of a control group who did 
not. The researchers concluded that there was no ben-
efit to prescribing tenofovir in the third trimester of 
pregnancy.(2)
These results contrast with the thinking that the 
AASLD has carefully substantiated and cultivated in 
the hepatology community in recent years. The con-
clusion reached by the researchers of this study is 
counterintuitive, because 3 patients in their placebo 
group developed hepatitis B, whereas none in the 
treated group became infected. It is noteworthy that 
the mothers of all 3 infected infants in the treated 
group had HBV-DNA levels of more than 7.8 log10 
IU/mL. Such high viral loads may well be refractory to 
antiviral rescue during pregnancy. However, there are 
certainly a substantial number of mothers with viral 
loads somewhere between 200,000 and 1 million who 
can benefit from tenofovir. This particular trial sim-
ply cannot define the most precise group of potential 
beneficiaries.
A randomized, open-label trial published in 2016 
studied 200 mothers with viral loads greater than 
200,000 IU/mL and concluded that the rate of moth-
er-to-child transmission was lower among those who 
received tenofovir disoproxil fumarate therapy than 
among those who received care without antiviral ther-
apy. The researchers endorsed the use of tenofovir as 
outlined in the recent AASLD guidelines. We are not 
told viral loads of the mothers of tenofovir failures 
in this 2016 study, but it is possible that these moth-
ers had initial viral loads that were several orders of 
magnitude greater than other viremic mothers who 
may have responded.(3)
It is therefore not reasonable to conclude from the 
March 2018 controlled trial that tenofovir is of no ben-
efit to mothers with viral loads greater than 200,000 
IU/mL. There may be, however, a higher threshold 
beyond which tenofovir will no longer do the job. For 
the time being, the new AASLD guidelines must be 
followed. Perhaps, in the future, there will be a more 
potent antiviral agent that can eradicate much higher 
viral loads during pregnancy.
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REPLY:
Prevention of mother-to-child transmission of 
hepatitis B virus (HBV) is a major component of 
the HBV elimination efforts in every country. We 
thank Drs. Mubarak and Ferstenberg for highlight-
ing the American Association for the Study of Liver 
Diseases (AASLD) 2018 updated hepatitis B guid-
ance on prevention of mother-to-child transmission(1) 
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and conclusions from a recently published randomized 
clinical trial by Jourdain et al. of tenofovir disoproxil 
fumarate (TDF) versus placebo in pregnancy.(2) In the 
Jourdain et al. study, TDF was not associated with a sta-
tistically significant reduction in perinatal transmission 
of HBV, but the 2% rate of perinatal transmission with 
placebo was much lower than the expected 12%, leaving 
the study underpowered to detect a statistically signifi-
cant difference. Notably, no infants became infected in 
the TDF-treated group, similar to another randomized 
trial comparing third-trimester TDF to placebo.(3)
The cornerstone of prophylaxis of infants born to 
HBV surface antigen–positive women is timely admin-
istration of passive immunization with hepatitis B 
immune globulin (HBIG) and HBV vaccine. HBIG 
and the first dose of the vaccine should be given as 
soon as possible after birth and no later than 12 hours 
postdelivery.(1) Most strikingly, the Jourdain et al. study 
achieved a very short interval between birth and admin-
istration of HBIG (median 1.3 hours) and HBV vaccine 
(median 1.2 hours),(2) thereby demonstrating the effec-
tiveness of ideally delivered immunoprophylaxis. Despite 
this, transmission still occurred only in the placebo (and 
not the TDF-treated) group. Additionally, their results 
may not reflect “real-world” settings, where timing of 
HBIG and vaccine is likely to be more variable. Indeed, 
only 71.1% of newborns in the United States in 2016 
received the first dose of HBV vaccine within 3 days 
of birth.(4) Thus, the AASLD continues to advocate for 
use of antiviral therapy in the third trimester for women 
with high HBV DNA levels as an additional measure to 
reduce perinatal transmission of HBV.
Mubarak and Ferstenberg suggested that women 
with very high HBV DNA levels may be at risk for 
failure of antiviral prophylaxis. In our prior systematic 
review, an HBV DNA level of 200,000 IU/mL was 
the threshold below which perinatal transmission was 
not seen. The AASLD guidance recommends anti-
viral therapy if baseline HBV DNA is >200,000 IU/
mL, a threshold selected to reduce the rate of perinatal 
transmission to as close to zero as possible. In clinical 
trials of immune active hepatitis B e antigen–positive 
persons, median decline in HBV DNA was –3, –3.78, 
–4.36, and –4.92 log10 after 4, 8, 12, and 16 weeks 
of TDF.(5) Thus, for women with very high levels of 
HBV DNA (>109 IU/mL) during pregnancy, starting 
treatment earlier than weeks 28-32 may be prudent to 
achieve HBV DNA ≤200,000 IU/mL at the time of 
delivery. The current AASLD guidance recommen-
dation to start TDF at weeks 28-32 of gestation is 
reasonable; however, a more individualized approach 
based on maternal viral load earlier in pregnancy and 
anticipated time of delivery could be considered to 
achieve sufficient suppression of HBV DNA to pre-
vent HBV transmission.
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Allogeneic Mesenchymal Stem Cells Therapy for the Treatment of 
Hepatitis B Virus–Related Acute-on-Chronic Liver Failure
TO THE EDITOR:
We read with great interest the recent publica-
tion by Lin et al.(1) Recently, mesenchymal stem cells 
(MSC) have been considered a novel and effective 
therapy for liver diseases such as liver fibrosis, cir-
rhosis, and liver failure. In this paper, the authors 
demonstrated the significant survival benefit of allo-
geneic bone marrow MSC (BMSC) for hepatitis B 
virus–related acute-on-chronic liver failure (ACLF) 
in comparison with standard medical treatment. 
However, optimization of this therapeutic strategy is 
more valuable for MSC treatment. There are several 
aspects that should be taken into consideration. First, 
the number of infused MSC is the primary consid-
eration. In this study, patients in the BMSC group 
received different infusion doses ranging from 1.0 to 
10 × 105 cells/kg. Several previous studies revealed 
that a larger number of infused MSC was associ-
ated with more satisfied efficacy. Nakamura et al.(2) 
study showed that transplantation of human CD34+ 
cells after chronic liver injury aroused the regenera-
tion of liver function in a dose-dependent manner. 
Therefore, in BMSC efficacy assessment, it is neces-
sary to conduct subgroup analysis based on the differ-
ent cell dosages. Second, studies showed that infusion 
of MSC through hepatic artery improved liver func-
tion more effectively than intravenous perfusion.(3) 
This may be because transplantation through hepatic 
artery can deliver a larger number of transplanted 
cells to the damaged liver parts, thereby stimulat-
ing hepatic regeneration more efficiently. Therefore, 
investigation of the different effects of BMSC for 
ACLF using different routes of cell administration 
will benefit its clinical application. Lastly,  allogeneic 
BMSC were used for the treatment ACLF in this 
study. Human umbilical cord is another source of 
MSC that demonstrates advantages over BMSC 
with a wider range of collection sources, easier non-
invasive approach, and fewer ethical constraints.(4) 
Therefore, using umbilical cord instead of bone mar-
row as the cell source may be more feasible for the 
treatment of ACLF. On the other hand, the number 
of cells extracted from an umbilical cord specimen 
is far more than that of a bone marrow specimen, 
which can eliminate the individual differences of 
MSC therapeutic effects. In summary, it would be 
more meaningful if the authors can investigate these 
aspects in the curative effects of BMSC therapy.
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